12 trends tracked about this subject — the full history, oldest to newest below.
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
A small Adelaide University sheep study found a single dose of semaglutide cut maternal cardiac output and fetal oxygen levels within two hours, raising new questions about GLP-1 drug safety during pregnancy.
A major review of nearly 200 preclinical studies and major clinical trials finds that GLP-1 obesity drugs may protect the brain, but randomized trials have not shown a clear cognitive benefit.
A new observational study links weight regain following the use of obesity medications to an increased risk of suicidal thoughts.
Ozempic’s “temporal hollowing” side effect is sparking a surge in cosmetic procedures, prompting medical warnings.
Health experts and trainers are advocating for targeted strength training for adults over 50 to combat age-related muscle loss and improve longevity.
Reports link Ozempic and similar GLP‑1 drugs to altered smell and taste, sparking a new “Ozempic mouth” discussion
GLP-1 drugs like Ozempic may offer an unexpected fertility boost for obese men, reshaping reproductive health approaches
New clinical research presented at ASCO26 suggests a potential link between GLP-1 receptor agonist medications and reduced cancer risk.
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
GLP-1 weight-loss drugs are exposing a hidden health crisis: nutrient deficiencies linked to rapid weight loss
US employers may halt GLP-1 drug coverage in 2027 amid rising costs and usage spikes